Radiotranscriptomics in papillary thyroid carcinoma complement current noninvasive risk stratification system
Dong Hyun Seo1, Eunjung Lee2, Jung Hyun Yoon3
1Department of Internal Medicine, Open NBI Convergence Technology Research Laboratory, Yonsei University College of Medicine, Seoul 03722, South Korea.
Science Advances
|August 29, 2025
Summary
A new radiomics score accurately predicts papillary thyroid carcinoma (PTC) risk noninvasively. This tool aids in stratifying patients, potentially reducing overtreatment and guiding active surveillance for better thyroid cancer management.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Papillary thyroid carcinoma (PTC) often has a good prognosis, but overtreatment is common due to a lack of noninvasive risk assessment tools.
- Accurate preoperative risk stratification is crucial for optimizing patient management and avoiding unnecessary interventions.
Purpose of the Study:
- To develop and validate a radiomics-based approach for enhancing the preoperative assessment and risk stratification of papillary thyroid carcinoma.
- To identify reliable noninvasive tools for distinguishing between indolent and aggressive PTC subtypes.
Main Methods:
- Analysis of imaging features from 255 PTC patients using unsupervised clustering to identify distinct tumor groups.
- Construction and validation of a radiomics score using internal and external datasets.
- Transcriptomic analysis to investigate molecular profiles of identified tumor clusters.
Main Results:
- Three distinct tumor clusters were identified, with Cluster 2 showing favorable clinical and molecular characteristics.
- The radiomics score achieved high diagnostic accuracy (AUC=0.98) in predicting favorable features and treatment responses.
- Transcriptomic analysis revealed immune activation and survival-related gene expression in the favorable cluster.
Conclusions:
- A validated radiomics score offers a precise, noninvasive tool for preoperative risk stratification in PTC.
- This approach can aid in identifying patients suitable for active surveillance, potentially reducing overtreatment.
- The findings may complement existing diagnostic frameworks for personalized thyroid cancer management.


